FAITH NGUYEN: Open Payments
NPI 1699175737 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$587 in 29 payments from 10 companies in 2025. Trend: 2023 $21 · 2024 $422 · 2025 $587
Food & beverage: $587
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $161 |
| ABBVIE INC. | 5 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Indivior Inc. | 1 | $14 |
Products named: REXULTI, VRAYLAR, CAPLYTA, Auvelity, FANAPT, TRINTELLIX, Qelbree, ARISTADA.
Industry payments across MD — which companies pay providers there.
